Gedeon Richter

RICHT · Budapest Stock Exchange

Public Market Listing

RICHTBudapest Stock Exchange

Budapest Stock Exchange primary exchange listing

Live quotes, historical charts, and market capitalization for Gedeon Richter are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
7Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Dopamine D3/D2 receptor (partial agonist)Small molecule
Major Depressive DisorderSchizophreniaBipolar DisorderBipolar Depression
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Cariprazine (Vraylar)Phase 3Schizophrenia
Est. primary completion 2026-12-15 · NCT03817502 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Cariprazine (Vraylar)Phase 3Depression, Bipolar I Disorder
Est. primary completion 2027-03 · NCT04777357 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 May 2025Approvalustekinumab-hmny (Starjemza)FDA approves STARJEMZA (ustekinumab-hmny), a Stelara biosimilar
US, FDA · Source ↗

Financial reports

No financial reports recorded.